Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Asset Writedowns and Impairment (2022)

Gyre Therapeutics (GYRE) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with $200000.0 as the latest value for Q1 2022.

  • On a quarterly basis, Asset Writedowns and Impairment changed N/A to $200000.0 in Q1 2022 year-over-year; TTM through Dec 2022 was $200000.0, a N/A change, with the full-year FY2022 number at $200000.0, changed N/A from a year prior.
  • Asset Writedowns and Impairment was $200000.0 for Q1 2022 at Gyre Therapeutics, up from $134000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $200000.0 in Q1 2022 to a low of $200000.0 in Q1 2022.